Search

Your search keyword '"Fusco FR"' showing total 111 results

Search Constraints

Start Over You searched for: Author "Fusco FR" Remove constraint Author: "Fusco FR"
111 results on '"Fusco FR"'

Search Results

1. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition.

2. Local synthesis of brain derived neurotrophic factor (BDNF) in the striatal cholinergic interneurons of the murine model of Huntington’s disease

3. Effects of phosphodiesterase inhibition on ERK phosphorylation in the R6/2 mouse model of Huntington’s disease

4. Cellular localization of ERK in the R6/2 mouse model of Huntington’s disease

5. Immunohistochemical localization of Receptor for advanced glycation end products (RAGE) in the R6/2 mouse model of Huntington’s disease

6. Distribution of TRPC1 receptors in dendrites of rat substantia nigra: a confocal and electron microscopy study.

7. Huntingtin distribution among striatal output neurons of normal rat brain.

8. Localization of ataxin-2 within the cerebellar cortex of the rat.

9. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease

11. Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission

12. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease

13. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease

14. A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation

15. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia

16. Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease

17. The distinct role of medium spiny neurons and cholinergic interneurons in the D2/A2A receptor interaction in the striatum: implications for Parkinson's disease

18. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

19. Up-regulation of P2X2, P2X4 receptor and ischemic cell death: prevention by P2 antagonists.

22. Diagnostic issues and capabilities in 48 isolation facilities in 16 European countries: data from EuroNHID surveys

23. Infection control management of patients with suspected highly infectious diseases in emergency departments: data from a survey in 41 facilities in 14 European countries

24. Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007

25. Localization of neuroglobin in the brain of R6/2 mouse model of Huntington's disease

26. Huntingtin polyQ Mutation Impairs the 17β-Estradiol/Neuroglobin Pathway Devoted to Neuron Survival

27. Efficient cultivation of neural stem cells with controlled delivery of FGF-2

28. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease

29. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease

30. Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition

31. Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease

32. A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation

33. Systemic inflammation accelerates neurodegeneration in a rat model of Parkinson's disease overexpressing human alpha synuclein.

34. Biobanking, digital health and privacy: the choices of 1410 volunteers and neurological patients regarding limitations on use of data and biological samples, return of results and sharing.

36. Neuroimmune pathways involvement in neurodegeneration of R6/2 mouse model of Huntington's disease.

37. Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease.

38. Neuropathology of the Basal Ganglia in SNCA Transgenic Rat Model of Parkinson's Disease: Involvement of Parvalbuminergic Interneurons and Glial-Derived Neurotropic Factor.

39. Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington's Disease.

40. A2A Receptor Dysregulation in Dystonia DYT1 Knock-Out Mice.

41. Modulation of Inflammasome and Pyroptosis by Olaparib, a PARP-1 Inhibitor, in the R6/2 Mouse Model of Huntington's Disease.

42. Pyroptotic cell death in the R6/2 mouse model of Huntington's disease: new insight on the inflammasome.

43. Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease.

44. Dystonia: Sparse Synapses for D2 Receptors in Striatum of a DYT1 Knock-out Mouse Model.

45. Early balance training with a computerized stabilometric platform in persons with mild hemiparesis in subacute stroke phase: A randomized controlled pilot study.

46. Early body weight-supported overground walking training in patients with stroke in subacute phase compared to conventional physiotherapy: a randomized controlled pilot study.

47. Modulation of Phospho-CREB by Systemically Administered Recombinant BDNF in the Hippocampus of the R6/2 Mouse Model of Huntington's Disease.

48. Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6/2 mouse model of Huntington's disease.

49. Bilateral upper limb rehabilitation with videogame-based feedback in corticobasal degeneration: a case reports study.

50. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Catalog

Books, media, physical & digital resources